–
Статьи в журналах
-
- 2020 Multicenter, open-label, post-authorization safety study (PASS) of elsulfavirine (Elpida®) used in the first-line therapy for HIV-1 infected patients added to standard ART (NNRTI + two NRTIs). HIV Glasgow – Virtual, 5–8 October 2020
- Yakubova E., Kravchenko A., Shimonova T., Bessarab T., Sizova N., Stepanova E., Pokrovskaya A., Kuimova U., Kuznetsova A., Radzikhovskaya M., Pozdnyakova L., Ulyanova Y., Gusev D., Yakovlev A., Kovelenov A., Inozemtseva E., Baranovsky S., Arsienko R., Remeeva J., Corritori S., Savchuk N., Dukes I., Weichert A., Murphy D., Richman R.
- в журнале Journal of the International AIDS Society, издательство BioMed Central (London), том 23, № S7, с. 21-21 DOI